Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Molecular underpinnings of metastatic small renal masses
Payal Kapur, Daria Beshnova, Hua Zhong, Ruby Sharma, Pooja Ghatalia, Angela Yoo, Daniel D. Le, Ratna Mukhopadhyay, Alana Christie, Jeffrey Miyata, Shuanzeng Wei, Rana R. McKay, Dinesh Rakheja, Satwik Rajaram, Robert G. Uzzo, A. Ari Hakimi, Zora Modrusan, James Brugarolas
Payal Kapur, Daria Beshnova, Hua Zhong, Ruby Sharma, Pooja Ghatalia, Angela Yoo, Daniel D. Le, Ratna Mukhopadhyay, Alana Christie, Jeffrey Miyata, Shuanzeng Wei, Rana R. McKay, Dinesh Rakheja, Satwik Rajaram, Robert G. Uzzo, A. Ari Hakimi, Zora Modrusan, James Brugarolas
View: Text | PDF
Research Article Clinical Research Genetics Oncology

Molecular underpinnings of metastatic small renal masses

  • Text
  • PDF
Abstract

Metastases in renal cell carcinoma (RCC) typically arise from large primary tumors. However, a subset of patients with small renal masses (SRMs; ≤4 cm) can develop metastatic disease. Identifying these tumors is clinically important, as many SRMs are managed with active surveillance, and their study may provide insight into the early acquisition of metastatic competence. It remains unclear whether these tumors acquire distinct metastatic programs or instead show premature activation of the same aggressive programs typically associated with larger tumors. Here, we performed integrated morphological and molecular profiling of a multiinstitutional cohort of metastatic SRMs, including whole-exome sequencing and RNA-Seq, using nonmetastatic primary tumors as controls. Among metastatic, non–clear cell SRMs, we identified NF2-altered tumors, ELOC-mutated RCC, and an mTOR-driven eosinophilic vacuolated tumor. Metastatic clear cell SRMs were enriched by multi-hit aggressive genotypes, including recurrent losses of chromosomes 8p, 9, and 14q, as well as co-occurring driver alterations (≥2 events), including BAP1 and mTOR pathway genes. Transcriptomic analyses revealed enrichment of the non-negative matrix factorization 3 (NMF3) subtype from the IMmotion151 trial-based taxonomy, along with metabolic rewiring and reduced cytotoxic immune effector function. Collectively, these findings identify molecular programs associated with metastatic competence in SRMs, highlight the importance of genomic studies of equivocal non-clear cell SRMs, and provide a biological framework for risk stratification in patients often considered for active surveillance.

Authors

Payal Kapur, Daria Beshnova, Hua Zhong, Ruby Sharma, Pooja Ghatalia, Angela Yoo, Daniel D. Le, Ratna Mukhopadhyay, Alana Christie, Jeffrey Miyata, Shuanzeng Wei, Rana R. McKay, Dinesh Rakheja, Satwik Rajaram, Robert G. Uzzo, A. Ari Hakimi, Zora Modrusan, James Brugarolas

×

Figure 1

Integrated genomic profiling refines the classification of metastatic non–clear cell SRMs and identifies aggressive molecular subtypes.

Options: View larger image (or click on image) Download as PowerPoint
Integrated genomic profiling refines the classification of metastatic no...
(A) Oncoplot showing recurrent somatic (nonsynonymous) alterations along with variant classification, mutation frequency, and arm-level copy-number changes across SRM-Mnon-ccRCC cases (n = 21), annotated by tissue type (primary or metastasis), normal reference type, and revised histological classification. To avoid duplication, a single sample for MSK015 (T1) is shown. (B) Representative H&E images from the eosinophilic vacuolated tumor (EVT-MSK015) show 2 morphologically distinct regions, including a classic EVT component (T1a-higher magnification shown in green box) and a more advanced solid component (T1b-higher magnification shown in red box) (scale bars: 1,000 μm [middle], 100 μm [top and bottom]). Left panels show EVT showing positive membranous CD117, rare focal cytokeratin 20 expression restricted to the classic EVT area, and diffuse phospho-S6 expression (all 200× original magnification). (C) Oncoplot along with phylogeny tree from multiregional genomic profiling of the EVT case (4 sampled regions: 2 classic areas, MSK015 T1 and T1a, a solid area, MSK015 T1b, and a lymph node metastasis, MSK015 M1a). Oncoplot shows shared and region-specific alterations. The phylogeny tree suggests that the metastasis arose from the solid area (T1b), which evolved from the classic EVT region (T1/T1a). BHP RCC, biphasic hyalinizing psammomatous renal cell carcinoma; ccRCC, clear cell renal cell carcinoma; Del, deletion; ELOC RCC, ELOC-mutated renal cell carcinoma; EVT, eosinophilic vacuolated tumor; FH RCC, fumarate hydratase–deficient renal cell carcinoma; Ins, insertion; LOH, loss of heterozygosity; M, metastatic tumor; PRCC, papillary renal cell carcinoma; RCC, renal cell carcinoma; T, primary tumor; tRCC, translocation renal cell carcinoma.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts